Highlights

• Telix closed at AU$15.76, the low of the day and below the AU$16.65 price at which ITM's sellers are being issued shares.
• Telix is paying about 6x revenue for a business that loses money at the group level, and all of ITM's profit sits in its isotope division.
• ITM-11 is not yet FDA-approved. A Complete Response Letter received in August makes resubmission a condition to closing.

Telix Pharmaceuticals (ASX: TLX) closed down 11.71% at AU$15.76, a fall of AU$2.09, and finished at the low of a AU$15.76 to AU$17.40 range. The stock entered the announcement near the top of its 52-week range, so the deal landed with little valuation cushion.

The deal

Telix will pay US$1.65 billion upfront, cash-free and debt-free, for ITM Isotope Technologies Munich. That is about US$1.25 billion in 105.8 million new shares priced at US$11.84 (the AU$16.65 30-day VWAP at 0.71 AUD/USD), US$302 million of assumed net debt, and US$96 million of rollover and expenses. Up to US$700 million more is contingent on ITM-11, with US$250 million tied to FDA approvals and up to US$450 million to FY2030 sales above US$150 million.

Why the market sold

• Dilution and overhang. The share count rises about 31%, leaving existing holders with 76.3%. Because the share count is fixed, ITM's sellers now hold paper worth less than the headline. At today's close and the same exchange rate, the shares are worth roughly US$1.18 billion, not US$1.25 billion. Escrow runs up to 15 months, after which supply could return to the market.
• Price versus profit. US$1.65 billion is about six times ITM's 2025 revenue of US$273 million. The isotope business justifies the interest, with EBITDA of US$77 million in 2025 and US$53 million in H1 2026, or about US$106 million annualised. On that figure we estimate the upfront price at roughly 15.6x. But ITM's group Adjusted EBITDA was -US$45 million in 2025 and -US$12 million in H1 2026, because therapeutics lost US$102 million and US$59 million. Telix is buying a profitable factory bundled with an expensive pipeline, and the maths depends on trimming the latter.
• The regulatory gap. ITM-11 beat everolimus in Phase 3, with median PFS of 23.9 versus 14.1 months. But the FDA issued a Complete Response Letter on 7 August 2026. Management says it is limited to manufacturing and third-party facility items, with no clinical deficiencies raised. In our view such issues are usually more tractable than clinical ones, but timing is uncertain. Resubmission, or an agreed path to it, is a closing condition, and the first US$100 million milestone needs approval by 31 December 2027.

What we are watching

• The November 2026 shareholder vote (a US$5 million fee applies if it fails)
• The 31 December 2026 end date
• The timing of the ITM-11 resubmission
• The COMPOSE interim analysis in H1 2027
• Delivery of the US$50 million targeted synergies

The strategic logic is sound: secured lutetium-177 supply and a route into neuroendocrine tumours. The debate is price, structure and timing.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au